Vanguard Group Inc F Star Therapeutics, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$4.09 - $6.86 $81,570 - $136,815	-19,944 Reduced 6.38%	292,664 $1.85 Million
Q3 2022 Nov 14, 2022	SELL	$5.41 - $6.74 $3.12 Million - $3.89 Million	-576,645 Reduced 64.85%	312,608 $1.6 Million
Q2 2022 Aug 12, 2022	BUY	$2.18 - $6.39 $633,978 - $1.86 Million	290,816 Added 48.6%	889,253 $5.57 Million
Q1 2022 May 13, 2022	SELL	$2.77 - $5.36 $413,458 - $800,049	-149,263 Reduced 19.96%	598,437 $2.12 Million
Q4 2021 Feb 14, 2022	BUY	$4.71 - $7.38 $14,492 - $22,708	3,077 Added 0.41%	747,700 $3.75 Million
Q3 2021 Nov 12, 2021	SELL	$5.2 - $8.42 $148,678 - $240,744	-28,592 Reduced 3.7%	744,623 $5.45 Million
Q2 2021 Aug 13, 2021	BUY	$6.57 - $10.71 $5.08 Million - $8.28 Million	773,215 New	773,215 $6.64 Million

44.7K

Ticker FSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,584,700
Description
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck c...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.